CRTI Exceptional Translational Research Award
The objective of MCC’s Cancer Research Translational Initiative (CRTI) Exceptional Translational Research Award. is to identify and fund outstanding translational research projects that will lead to sustainable high impact external funding. Translation is in any area of cancer research that applies or accelerates discovery into testing in clinical or population settings.
ATM inhibition for the treatment of TP53-altered metastatic prostate cancer: A novel synthetic lethality
Emmanuel Antonarakis, MD, Division of Hematology, Oncology, and Transplantation, Medical School
R. Stephanie Huang, PhD, Department of Experimental and Clinical Pharmacology, College of Pharmacy
Justin Drake, PhD, Department of Pharmacology, Medical School
Hai Dang Nguyen, PhD, Department of Pharmacology, Medical School
Ali Arafa, MD, Department of Pharmacology, Medical School
Impact of discrimination on cardiovascular health in breast cancer survivors treated with aromatase inhibitors: link to gut microbiome
Leena Hilakivi-Clarke, PhD, Department of Food Science and Nutrition, College of Food, Agriculture, and Natural Resource Sciences
Anne Blaes, MD, MS, Division of Hematology, Oncology, and Transplantation, Medical School
Christopher Staley, PhD, Department of Surgey, Medical School
Candyce Kroenke, MPH, ScD, Division of Research, Kaiser Permanente
Annie Lin, PhD, Hormel Institute
Levi Teigen, PhD, RD, Department of Food Science and Nutrition, College of Food, Agriculture, and Natural Resource Sciences
Pre-clinical testing of a B7-H3 targeting chimeric antigen receptor NK (B7-H3 CAR-iNK) construct in preparation for a first-in-human glioblastoma trial
Jianfang Ning, PhD, Department of Neurosurgery, Medical School
Jeffrey Miller, MD, Division of Hematology, Oncology and Transplantation, Medical School
Minnesota Annotated Genomics In Cancer (MAGIC) - An interactive multi-omics portal to study Masonic Cancer Center prostate cancer patients
Justin Hwang, PhD, Division of Hematology, Oncology and Transplantation, Medical School
Emmanuel Antonarakis, MD, Division of Hematology, Oncology and Transplantation, Medical School
Jinhua Wang, PhD, Institute for Health Informatics, Office of Academic Clinical Affairs
RET Degraders for Treating Neuroendocrine Prostate Cancer
Justin Drake, PhD, Department of Pharmacology, Medical School
Daniel Harki, PhD, Medicinal Chemistry, College of Pharmacy
Engineered T cell therapy for poor prognosis cancers
Ingunn Stromnes, PhD, Department of Microbiology & Immunology, Medical School
Jeffrey Miller, MD, Division of Hematology, Oncology and Transplantation, Medical School